BRPI1014756A2 - composição farmacêutica de duloxetina ou sais farmaceuticamente aceitáveis da mesma - Google Patents

composição farmacêutica de duloxetina ou sais farmaceuticamente aceitáveis da mesma

Info

Publication number
BRPI1014756A2
BRPI1014756A2 BRPI1014756A BRPI1014756A BRPI1014756A2 BR PI1014756 A2 BRPI1014756 A2 BR PI1014756A2 BR PI1014756 A BRPI1014756 A BR PI1014756A BR PI1014756 A BRPI1014756 A BR PI1014756A BR PI1014756 A2 BRPI1014756 A2 BR PI1014756A2
Authority
BR
Brazil
Prior art keywords
duloxetine
pharmaceutically acceptable
pharmaceutical composition
acceptable salts
salts
Prior art date
Application number
BRPI1014756A
Other languages
English (en)
Inventor
Girish Kumar Jain
Inderjeetsingh Huda
Kasturi Roy
Munish Talwar
Ritesh Kapoor
Sanjay Mate
Original Assignee
Wockhardt Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Research Center filed Critical Wockhardt Research Center
Publication of BRPI1014756A2 publication Critical patent/BRPI1014756A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
BRPI1014756A 2009-06-25 2010-06-24 composição farmacêutica de duloxetina ou sais farmaceuticamente aceitáveis da mesma BRPI1014756A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1507MU2009 2009-06-25
IN1506MU2009 2009-06-25
PCT/IB2010/052879 WO2010150219A1 (en) 2009-06-25 2010-06-24 Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
BRPI1014756A2 true BRPI1014756A2 (pt) 2016-04-19

Family

ID=42840957

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014756A BRPI1014756A2 (pt) 2009-06-25 2010-06-24 composição farmacêutica de duloxetina ou sais farmaceuticamente aceitáveis da mesma

Country Status (4)

Country Link
US (1) US8758779B2 (pt)
BR (1) BRPI1014756A2 (pt)
CA (1) CA2765635C (pt)
WO (1) WO2010150219A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008129501A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of duloxetine
WO2012163546A1 (en) * 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
CN102579403B (zh) * 2011-12-26 2013-08-21 天津市嵩锐医药科技有限公司 盐酸度洛西汀药物组合物
WO2014018075A1 (en) 2012-07-23 2014-01-30 Crayola, Llc Dissolvable films and methods of using the same
US9839626B1 (en) 2016-12-14 2017-12-12 Sun Pharmaceutical Industries Limited Duloxetine sprinkles
CN108403622B (zh) * 2018-05-24 2021-05-11 杭州求是医学科技有限公司 一种水凝胶及应用该水凝胶制作降温贴的工艺
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
JP7390830B2 (ja) * 2019-09-11 2023-12-04 日本食品化工株式会社 医薬活性化合物の苦味抑制剤及び苦味抑制方法
CN113845152A (zh) * 2021-08-30 2021-12-28 蜂巢能源科技有限公司 镍锰酸锂正极材料、其制备方法和锂离子电池
EP4655005A1 (en) * 2023-01-27 2025-12-03 Bayer HealthCare LLC Taste-masking with a multi-component physical barrier

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
GB9402029D0 (en) 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SI1113797T1 (sl) 1998-09-15 2010-02-26 Lilly Co Eli Uporaba duloksetina pri zdravljenju fibromialgije
US20060182796A1 (en) 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
US20100285123A1 (en) 2005-06-20 2010-11-11 Rudresha Korlakunte Virupakshalah Prasad Controlled Release Dosage Formulation of Duloxetine
US8093408B2 (en) 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
US20080003296A1 (en) * 2005-07-11 2008-01-03 Ketner Rodney J Amorphous Cyclodextrin Compositions
DE102005041860A1 (de) 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
WO2008129501A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of duloxetine
WO2009084017A2 (en) 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride

Also Published As

Publication number Publication date
US8758779B2 (en) 2014-06-24
CA2765635A1 (en) 2010-12-29
WO2010150219A1 (en) 2010-12-29
US20120164216A1 (en) 2012-06-28
CA2765635C (en) 2016-09-06

Similar Documents

Publication Publication Date Title
BRPI1014756A2 (pt) composição farmacêutica de duloxetina ou sais farmaceuticamente aceitáveis da mesma
NL301291I2 (nl) sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl) Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301305I2 (nl) Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
BRPI0916922A2 (pt) composição farmacêutica de liberação prolongada de entacapona ou sais da mesma
NL301035I2 (nl) upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl) alpelisib of een farmaceutisch aanvaardbaar zout ervan
BRPI0916877A2 (pt) composição farmacêutica e administração da mesma
BR112012008082A2 (pt) composição farmacêutica e adminstrações da mesma
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
DK3097925T3 (da) Farmaceutisk sammensætning
PL2398464T3 (pl) Kompozycja farmaceutyczna do inhalacji
BRPI1004940A2 (pt) composição farmacêutica
BRPI0905952A2 (pt) Composto e sais do mesmo e compição farmacêutica
LT3061445T (lt) Labai koncentruotos farmacinės kompozicijos
DK2395834T3 (da) Natriumnitrit-holdige farmaceutiske sammensætninger
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
PL2468281T3 (pl) Kompozycja farmaceutyczna zawierająca pochodną chinoliny
PT2405942T (pt) Produto de administração oral
IT1394860B1 (it) Composti farmaceutici
BRPI1015939A2 (pt) composição farmacêutica
DK2464342T3 (da) Farmaceutisk formulering mod stofmisbrug
NO2023002I1 (no) Lasmiditan or a pharmaceutically acceptable salt thereof
EP2642993A4 (en) COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF OR PHARMACEUTICALIZED SALT OF ROTIGOTINE OR ITS DERIVATIVES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]